Background. Traumatic brain injury refers to a broad range of neurological, cognitive, and emotional factors that result from the application of an external force to the head. Individuals recovering from traumatic brain injury will frequently experience acute and chronic pain.
Introduction
Traumatic brain injury (TBI) is specifically defined as an injury caused by an external force such as a direct blow to the head or exposure to a shock wave. With an estimated global incidence of 106 per 100,000 people, TBI is a leading cause of death and disability worldwide [1] [2] [3] . The majority (75-80%) of all TBI cases are mild in nature and are accompanied by the rapid resolution of the immediate symptoms, including disorientation, dizziness, nausea, and balance problems (Table 1) [4]. The most common mechanism of TBI in the civilian population is falls, although the mechanism of motor vehicle accidents (MVAs) supersedes falls among adolescents and young adults [5] . The incidence of TBI is particularly high in deployed military populations, largely due to blast injuries from improvised explosive devices and more conventional munitions [6] . Cumulative trauma to the brain can occur in collision/contact sports (i.e., boxing, football, and hockey) and, among military personnel, following exposure to frequent shock waves from blasts [7] . This type of repetitive TBI represents a complex problem for the field due to the difficulty in its quantification and the possibility that it has consequences distinct from single injuries [8] . Whether from single or multiple injuries, however, TBI represents a common but understudied form of injury to the brain.
It has become clear that pain in the forms outlined below is common and sometimes persistent after TBI. Very little information, however, is available concerning the mechanisms supporting that pain. Such information is critical in order to 1) develop approaches for reducing the occurrence of pain after TBI, 2) provide prognostic information to patients suffering post-TBI pain, and 3) rationally design post-TBI pain treatments. In the sections below, we outline the scope and nature of the problem, and then turn to mechanisms potentially contributing to post-TBI pain. Publications containing information related to pain and TBI were identified using an English language PubMed/MEDLINE search without restriction on dates using combinations of the terms "traumatic brain injury," "pain," and "headache." For the mechanistic sections, additional searches of the same database were conducted, adding "descending inhibition," "neuroinflammation," "neurodegeneration," "synapse," "neurotransmitter," "epigenetics," and additional terms. Papers evaluating pain specifically or known mechanisms related to pain signaling were considered further.
The Frequency of Pain After TBI
In addition to the well-recognized consequences of TBI, including cognitive changes, motor deficits, and sensory abnormalities, accumulating evidence suggests that acute and chronic pain are also common after TBI. Acute pain, usually associated with defined tissue damage, typically lasts up to several weeks and is expected to abate when healing has occurred, for example, in the case of TBI, fractured skull. Chronic pain, while having no single definition, is ongoing and continues for three to six months or longer. Chronic pain is often not as closely associated with tissue damage as with acute pain.
A review that examined data from more than 23 studies, involving 4,200 TBI patients, revealed that 51.5% of civilian TBI patients experienced chronic pain, although the frequency of chronic pain among veterans was somewhat lower in these samples (43.1%) [9] . One set of reasons explaining the differing rates could be the way in which the patients are identified. For example, in the military, statistics of TBI incidence are often based on patient self-reports or extrapolations of data sets that can differ widely (22-95%), possibly obscuring the actual frequency of TBI. Some studies have calculated TBI incidence based on "regional injury casualty reports" and exclude service members who returned to duty within 72 hours of injury. With such an approach, cases of mild TBI, often not accompanied by visible wounds, may be substantially underreported [10] . This is a key issue as Sherman and colleagues have stated that injury and biological factors are often not sufficient to account for the development of chronic pain in the TBI population [11] .
Even though longitudinal studies of TBI pain have demonstrated that some resolution of pain can occur over the first four to five years post-TBI, it is not clear what factors support persistence vs resolution of post-TBI pain [12] . TBIs can vary depending on the degree of associated physical (structural damage), cognitive (memory), and affective (anxiety, depression) consequences. The Department of Veterans Affairs (VA) and Department of Defense (DoD) have Clinical Practice Guidelines for Management of Concussion/Mild Traumatic Brain Injury that determine the severity of TBI based largely on objective physical findings such as an abnormal magnetic resonance image (MRI), the duration of loss or alteration of consciousness, and level of Glasgow outcome scale (GOS) scores (Table 1) . However, analyses of the relationship between the severity of the TBI and the likelihood of experiencing chronic pain have yielded unexpected results. In the analysis conducted by Nampiaparampil [13] , it was concluded that mild TBI was associated with a 75.3% rate of pain while moderate to severe TBI was associated with a 32.1% rate. However, as this author and others have pointed out, an assessment of a lower rate of pain in more severely injured patients may be due to difficulties in assessing their pain due to an altered level of consciousness, cognitive impairments, or verbal difficulties.
The Location of Pain After TBI
There is a strong preponderance of literature involving the study of headache after TBI as several studies have shown that the head is the common site of pain in these patients [12, 14] . Averaged across 12 studies, the rate of headache after TBI was 57.8% [13] , although some studies identified rates as high as 81% [12] . The current literature is inconsistent on the relationship between severity of TBI and post-traumatic headache (PTH). Several studies have found an inverse relationship between severity of TBI and frequency of PTH The most common sites of pain aside from the head are the neck, shoulders, back, and upper and lower limbs. This pain has been characterized as primarily musculoskeletal [24] . In addition, pain may result from several types of injuries co-occurring with TBI, including phantom limb pain, stump pain, and other forms of pain from damaged nerves [25] . Approaches to managing TBI-related extracranial pain are largely lacking. In fact, outcomes from standard pain treatments may be worse in patients with a history of TBI. A case in point is that soldiers with blast injuries are less likely to respond to multidisciplinary pain treatment than soldiers with other mechanisms of injury [26] . What appears to be needed is the development of approaches to multifactorial TBIrelated pain problems with an emphasis on the specific problems of individual patients. This is consistent with recent calls for "personalized" or "precision" approaches to pain management in which mechanisms and other factors supporting pain are identified prior to initiating treatments [27] . 
Less Common Pain Syndromes Resulting from TBI

Mechanisms Supporting Pain After TBI
The neurophysiologies of both TBI and pain are highly complex, and there exists a vast array of possible mechanisms potentially linking the two. In order to provide structure to this overview, mechanisms known to play roles in both TBI and chronic pain were identified and organized into four categories. We first consider macroscopic structures such as brain centers and tracts and proceed progressively to the cellular, synaptic, and, finally, molecular levels. For some of these mechanisms, specific evidence from clinical populations or animal studies supporting the link is available. For others, a functional link seems plausible but has not been demonstrated at this point. Differentiating between these mechanisms in individual patients may be critical as the approaches to treatment could be very different. It is also possible that multiple pain-supporting mechanisms may be active in individual patients.
Centers and Circuits Supporting Chronic Pain After TBI
Descending Regulation of Pain
An important aspect of the regulation of pain signaling is through systems of descending control ( Figure 1 ). Recently collected information suggests that dysfunctional descending inhibition can contribute to headaches resulting from TBI [59] . Subjects with chronic posttraumatic headache were found to have lower pressure pain thresholds and decreased conditioned pain modulation, supporting the conclusion that descending inhibitory control was deficient in these TBI patients [60] . Related to this, dysfunctional descending regulatory control in patients with stroke has been described that may contribute to chronic pain in these settings [61] . This descending system has broad importance in pain modulation; deficient descending inhibition has been associated with chronic postsurgical pain and fibromyalgia [62] . This system is particularly important for the regulation of pain arising from injured peripheral tissues such as skin, muscle, bone, and nerves [63] .
Descending inhibition mediated by the release of norepinephrine (NE) from the terminals of neurons with cell bodies located in the locus coeruleus (LC) and serotonin from the terminals of neurons with cell bodies in the rostroventromedial medulla (RVM) appears to be a principle mechanism of modulatory control [ Additional centers vulnerable to the effects of TBI can contribute to the modulation of pain signaling. Brain imaging studies in humans demonstrated a dysregulation of the periaqueductal gray (PAG) output, a major regulatory pathway affecting LC activity, following blast-mediated TBI [67] . These results have been complemented by a recent MRI study using diffusion tensor imaging [68] . In the latter investigation, the fractional anisotropy (FA; a measure of orderly tissue structure) was diminished in TBI patients suffering from chronic pain. In fact, there was a significant correlation between lower FA and elevated VAS pain scores. Thus traumatic events affecting the brain may support chronic pain by disrupting descending pathways affecting spinal cord dorsal horn nociceptive signaling mechanisms. Therapies directed at replacing noradrenergic tone such as those employing alpha-2 adrenergic agonists and selective serotonin-NE reuptake inhibitors may therefore constitute a rational therapeutic approach to reducing pain in some TBI patients.
Ascending Pathways
The spinothalamic tract (STT) is one of the principal pathways transmitting sensory information, including pain-related information to the brain from the spinal cord ( Figure 1 ). Neurons in the dorsal horn of the spinal cord receive input from sensory neurons and send axons across the midline that ascend to the ventral posterior nucleus (VPN) of the thalamus. Third-order Figure 1 Major nociceptive pathways. The spinothalamic tract (blue tract) is a major ascending spinal projection that transmits nociceptive, thermal, and nondiscriminative touch information to several thalamic nuclei including the ventral posterolateral nucleus, the intralaminar nuclei, and the posterior thalamic nucleus. Descending pain pathways transmit information from several brain regions including the cortex, hypothalamus, and amygdala to the periaqueductal gray (PAG) in the midbrain (red tract). Activation of the PAG neurons activates neurons within the rostroventral 
Cellular and Cytoarchitectural Processes Supporting Chronic Pain After TBI
A complex set of pathophysiological mechanisms is set in motion after an episode of TBI. The terms primary and secondary brain injury are often used to classify the involved injury processes (Figure 2 ). Primary events occur at the time of trauma and include physical disruption of brain parenchyma and blood vessels as well as the shearing of axons. Secondary injury refers to the damage to brain tissue not involved in the original injury that evolves over the hours and days following the primary insult. These secondary processes, often cellular in nature, are largely responsible for the delayed morbidity and mortality that results from TBI [96] .
Neuroinflammation
Neuroinflammation is most simply defined as inflammation involving nervous system tissue, which has been implicated in the pathogenesis of many diseases involving the central nervous system (CNS), ranging from neurodegenerative conditions, for example, Alzheimer's, Parkinson's, and Huntington's diseases [97] , to mental illness, for example, depression, anxiety, and obsessivemedulla (RVM). From the RVM (green tract), serotonin-and enkephalin-containing neurons project to the dorsal horn of the spinal cord via the dorsolateral funiculus and exert their inhibitory influences on nociceptive transmission. PAG neurons also activate noradrenergic-containing neurons within the locus coeruleus. This noradrenergic pathway (orange tract) descends in the ventrolateral funiculus to also have an inhibitory effect on the nociceptive transmission within the dorsal horn. Figure 1 Continued compulsive disorder [98] , to chronic pain syndromes, for example, neuropathic, back pain, and complex regional pain syndrome [99] . Neuroinflammation in the setting of TBI is a complex process involving both infiltrating and resident cells. Injury to the brain results in a breach of the blood-brain barrier (BBB), enabling recruitment of circulating neutrophils, macrophages, and lymphocytes to the injured site. Once activated, these cells release a number of inflammatory mediators that recruit additional immune cells to the site of injury and activate glia. The accumulation of blood-born immune cells within the brain parenchyma has been reported in human TBI as well as animal models of brain trauma [100] . In addition, neuroinflammation has been detected using brain imaging in the patient's years postinjury [101] .
Both microglia and astrocytes are activated in the setting of TBI. The activation of resident microglia plays a critical role in the response to brain injury [102] . When microglia become overactivated, however, they can produce and release multiple cytotoxic substances, including pro-inflammatory cytokines (e.g. Figure 2 Primary and secondary injury after traumatic brain injury (TBI). Injury to the brain after TBI occurs in two phases. Primary injury involves early events ranging from damage related to fracture of the skull and penetration of the brain parenchyma to force-related stretching of axons and hemorrhage. The complex mechanisms related to secondary injury include the following: Cerebral blood flow-both hypo-and hyperperfusion of the brain can occur after TBI. The main processes responsible for these pathophysiological states relate to vessel disruption, dysregulation of the mechanisms governing autoregulation, and vasospasm [89] . Ischemia and energy failure are two important consequences. Excitotoxicity: TBI is associated with the uncontrolled release of neurotransmitters, including the abundant excitatory neurotransmitter glutamate [90, 91] . The release of glutamate in excess of neuronal and astrocytic clearance mechanisms leads to the hyperexcitation of neurons, oxidative stress, membrane ionic imbalances, and ultimately cell death. In addition, the excess glutamate release has also been linked to some of the longer-term neuroplastic changes described below [92] . Cerebral edema: Brain trauma acts through dual vasogenic and cellular mechanisms to cause edema. Disruption of the blood-brain barrier (BBB) is characteristic of post-traumatic edema. One serious consequence is the elevation of intracranial pressure that can have adverse effects on the structure of the brain as well as cerebral perfusion [93] . Inflammation: One of the most serious consequences of TBI is cerebral inflammation. Inflammatory processes include the influx of neutrophils, the generation of cytokines, and the activation of the complement cascade. The consequences of inflammation after TBI include the direct damage attributable to inflammatory cells and mediators, breakdown of the BBB, and exacerbation of cerebral edema [88, 94, 95] . In fact, inflammatory mediators such as cytokines are often used as biomarkers of TBI severity and have some prognostic value concerning outcome [182] . Together the changes lead to functional changes of multiple types in multiple areas of the brain supporting chronic pain and multiple other TBI-related morbidities. Repair processes such as axonal regeneration, remyelination, and neuroprotection are critically dependent on the presence of neuroinflammation [108] . In addition, astrocytes play a crucial role in regulating extracellular glutamate levels, which can reduce glutamate excitotoxicity to neurons and other cells [109] .
In animal models of TBI, neuroinflammation has been shown to be present in many pain-related brain regions, including the thalamus [110] , cortex [111] , hippocampus [112] , amygdala [113] , and prefrontal cortex [113] . In addition, post-TBI neuroinflammatory changes may involve key pain modulatory centers including the PAG [68] . Cytokines produced by glia in the CNS are very strongly associated with chronic pain of multiple etiologies [114] . In this regard, TBI has been shown to increase the level of several neuroinflammation and pain-related cytokines including TNFa and IL-1b in several pain centers including the thalamus, hippocampus, substantia nigra, and hypothalamus [115] [116] [117] . Furthermore, studies have also implicated pain-related chemokine signaling in TBIinduced neuroinflammation through the CX3CR1 and CCR2 receptors [88, 118] . Additional neuroinflammationrelated mediators, including neurotrophins NGF and BDNF, are thought to modulate pain directly or through the enhancement of CNS neuroplasticity [119, 120] . For example, BDNF levels were increased in pain-related centers in the brain and spinal cord in both rodent and nonhuman primate models of TBI, and these changes could be detected up to one year postinjury [121, 122] .
Despite the strong rationale for the approach, clinical studies aimed at improving outcome measures in TBI patients by reducing neuroinflammation have, so far, yielded conflicting results. Furthermore, most studies focusing on the role of inflammatory mediators after TBI have failed to address the impact inflammatory mediators have on pain [38] . Dose and time course studies concerning the effects of inflammatory mediators on pain and recovery from TBI are therefore vital.
Neurodegeneration
Neurodegeneration involves the loss of structure and function of neurons, which can include additional mechanisms such as protein misfolding, axonal dysfunction, and the initiation of programmed cell death pathways [123] . Neurodegeneration is a major consequence of TBI, affecting a number of areas including the cortex, hippocampus, thalamus, amygdala, brainstem, and other areas. TBI is also a very well-established risk factor for progressive neurodegenerative diseases including PD, Alzheimer's disease (AD), and chronic traumatic encephalopathy (CTE) [124, 125] . In fact, the possibility of developing dementia increases two-to fourfold after a moderate to severe TBI. The risk is also increased in the setting of multiple generally mild TBIs suffered by amateur and professional athletes [126] . Furthermore, animal models of TBI assessed using diffuse tensor imaging have revealed chronic changes in the brain microstructure similar to those seen in humans with neurodegenerative conditions [127] .
While the link between long-term TBI-induced neurodegenerative changes and pain has not been carefully examined, neurodegenerative conditions including AD [128] and PD [129] are often associated with persistent pain. In PD, for example, neurodegeneration appears to lead to fundamental changes in the way pain-related and other sensory information is processed, as supported by alterations in lateral and medial pain pathways and the basal ganglia [130, 131] . Additional consequences of dysfunction of the dopamine-producing substantia nigra were presented earlier in the text. In AD, pain pathways are largely preserved, but the functional connectivity of the pain-related dorsolateral prefrontal cortex appears to be enhanced with additional pain-relevant brain centers such as the thalamus, cingulate cortex, and PAG [128, 132] . Thus neurodegenerative changes might support pain by disturbing the function of a variety of mechanisms within the brain. Whether therapies specifically targeted at limiting neurodegeneration could also limit pain after TBI remains uncertain.
Axonal Damage
Diffuse axonal injury (DAI) is a consequence of traumatic shearing forces brought about by rapid acceleration, deceleration, or rotation of the head [133] . DAI is most typically seen after MVAs, falls, and assaults. Shearing causes stretching of the axons, especially at the junctions between white matter and gray matter. Consequently, the axon endures trauma or separation where it communicates with the cell body, leading to an interruption in function and eventual Wallerian degeneration [134] . Further injury to the surrounding environment will occur due to the release of biochemical mediators from the severed axons. Thus, damage from DAI is often immediately manifest but can be progressive and evolve for more than a year [135] . Human studies have revealed DAI in pain-relevant centers and white matter tracts including those involving the thalamus [136] , cingulate [137] , prefrontal cortex [138] , and other areas following TBI. Many of these changes have been reproduced in a rat model of TBI [127] . Numerous therapies aimed at reducing the extent of DAI following TBI are being developed and tested, but at the present time the utility of targeting TBI-related DAI to reduce chronic pain remains an open question.
Synaptic and Biochemical Changes Supporting Pain After TBI
Synaptic Changes
The brain depends on interneuronal communication mediated by chemical and electrical synapses. The impact of TBI on the brain's synaptic structure has become the subject of many recent investigations, and it is now believed that synaptic loss is responsible for many of the short-and long-term consequences of TBI [139, 140] . Synaptic dysfunction has been demonstrated in brain tissues derived from TBI animals in vitro [141, 142] . Therefore, the ability of cell adhesion molecules such as neurexins and neuroligins to restore synaptic structure may be key to limiting the long-term functional damage caused by TBI [140] .
Synaptic dysfunction and synaptogenesis in pain-related centers may contribute to pain after TBI. For example, synaptic long-term potentiation in hippocampal tissue, a process intimately related to memory function and perhaps pain perception, is disrupted in experimental models of TBI [143, 144] . Similarly, neurons within the amygdala [145] and cortex [146] demonstrate altered synaptic functioning and hyperexcitability after TBI. In addition, biochemical evidence of synaptic damage and plasticity, including reduced levels of postsynaptic protein 95 and the presynaptic proteins synaptophysin and synapsin I, were observed in cortical and hippocampal tissue following TBI in laboratory animals [147, 148] . Related to this, it has been shown that synaptogenesis within the somatosensory cortex contributes to mechanical hypersensitivity in models of neuropathic pain [149] . This area of the cortex is frequently involved in TBI. Blocking this neuronal rewiring within the somatosensory cortex prevented the full development of mechanical allodynia.
Several agents have been proposed for the treatment of TBI focusing on synaptic integrity as a principal goal of therapy. In animal models, a broad array of agents have been used, including HMG-CoA reductase inhibitors [150] , NMDA receptor antagonists [151] , bioflavonoids including pycnogenol [152] , leukotriene synthesis [153] , and progesterone [154] . However, studies addressing a causative role for synaptic changes in pain after TBI remain to be done.
Molecular Changes Supporting Pain After TBI
Epigenetic Mechanisms
The term "epigenetics" refers to processes that alter gene activity without changing the underlying DNA sequence. Epigenetic changes can be influenced by several factors including age, the environment, and disease state. Some of the most important epigenetic mechanisms are DNA methylation, chromatin modification, and the expression of noncoding RNA species such as micro-RNA (miRNA). All of these processes have been noted to occur in brain tissue from TBI models. For example, global hypomethylation of DNA, relocalization of key methyltransferase enzymes, and demethylation have been reported in the brains of TBI rats including the two pain-related regions hippocampus and prefrontal cortex [155, 156] . Likewise, the acetylation of the histone protein subunit H3 has been observed in hippocampal and other tissues after TBI [157, 158] . Analyses of expression of miRNA after TBI have revealed significant alterations in various miRNA levels in several brain regions including the hippocampus, cortex as well as in peripheral leukocytes after injury [159, 160] . In fact, miR-16, -92a, -93, -191, -499, and let-7i have all been proposed as serum markers of TBI severity [160] [161] [162] .
The epigenetic mechanisms listed above also have clear roles in supporting or suppressing chronic pain [163, 164] . Specific to CNS level processes, global changes in brain DNA methylation have been shown after peripheral nerve injury [165] , while the inhibition of DNA methylation using the chemotherapeutic 5-azacytidine reduces pain-related changes [166] . The situation for manipulation of histone acetylation is complex, with observations of both pro-and antinociceptive effects of histone acetylation dependent on the pain model being used, route of administration, and timing relative to injury [167, 168] . Moreover, the expression of several pain-related genes in brain tissue has been shown to be under the control of miRNA, including the mu-opioid receptor [169] , the calcium ion channel, CaV1.2 [170] , BDNF [171] , and other molecules. The use of miRNA and related noncoding RNA species has been proposed as an avenue toward the control of chronic pain [172] , and the use of techniques to enhance levels of miR-7a and -124 has shown promise in this regard [173, 174] .
These observations raise the question as to whether epigenetic enzymes and mechanisms might constitute therapeutic targets for TBI treatment. Some efforts have been made in this area. The administration of the antidepressant fluoxetine, for example, enhanced histone acetylation, the expression of methyl-CpG-binding protein, and hippocampal neurogenesis although behavioral outcomes were not changed in a mouse model of TBI [175] . In order to assess the possibility that histone acetylation could alter nociceptive sensitization after TBI, Liang and coworkers administered the histone acetyltransferase inhibitor curcumin or the deacetylase inhibitor suberoylanilide hydroxamic acid to rats with experimental TBI [176] . They observed that reducing histone acetylation within the CAN after TBI reduced nociceptive sensitization. These results may be attributable to the reduced expression of BDNF after TBI [121] . The use of miRNA molecules as therapeutics for neurological conditions is an exciting new possibility but is at a relatively nascent Traumatic Brain Injury and Chronic Pain stage [177] . While none of these epigenetic mechanisms have been targeted clinically at this point for the treatment of TBI-related pain, many opportunities exist both in modulating overall processes in the case of DNA methylation and histone derivatization and in the regulation of specific gene levels in the case of miRNA.
Conclusions and Priorities
TBI is a very common form of injury affecting the young, the elderly, and the active. In addition to the betterknown consequences involving cognition, emotion, and motor control, chronic pain has more recently been recognized as a sequela of TBI. While there are many potential mechanisms explaining this problem, we have no clear understanding of which of them contribute specific types of pain in individual patients. Excluding headache, we completely lack evidence-based guidelines for the treatment of TBI-related pain. In order to improve our ability to help TBI patients with pain, a few top research priorities can be listed:
To Better Understand Loss of Descending Inhibitory Systems
Both human investigations and laboratory data suggest that dysfunction of descending inhibitory systems may contribute to pain after TBI. We need to define whether loss of descending inhibition supports specific types of TBI-related pain and whether particular mechanisms for acquiring TBI are more likely to lead to this type of dysfunction. Testing descending inhibition in humans is relatively simple, and test-retest reliability is high [178] . Generally, these paradigms involve the measurement of a thermal or mechanical pain threshold in one limb in the presence and absence of a second painful stimulus in another limb designed to activate descending modulatory pathways. Such measurements be used to focus therapy on descending inhibition-deficient patients by enhancing spinal serotonergic or noradrenergic tone either pharmacologically or through specific rehabilitative programs [179] .
To Better Understand the Potential Benefits of Targeting Inflammation After TBI
Clinical and laboratory evidence suggests that alterations in immune function and enhanced production of inflammatory mediators involving both the CNS and periphery accompany TBI. Regrettably, therapeutic trials involving immune modulators such as corticosteroids, ibuprofen, and the glial modulator minocycline have met with limited success in improving TBI outcomes [180] . However, there has been renewed focus on the targeting of specific deleterious cytokine mediators such as IL-1beta and TNFa [181] . Targeting these mediators specifically may leave intact the beneficial aspects of inflammation such as the production of neurotrophins and the clearance of cellular debris. Enhanced attention to the assessment of pain in such trials may be warranted.
To Better Understand How TBI Impacts the Likelihood of Developing Pain After Subsequent Trauma
Insofar as TBI may alter pain and analgesia-related pathways in the brain, it could reasonably be hypothesized that a history of TBI might be associated with a prolonged course of pain or even the development of chronic pain after subsequent injuries or surgery. If such an association was found, patients with TBI could consider that risk in their decisions as to whether or not to undergo surgery. In addition, augmented attention to postoperative pain control and emphasis on adherence to rehabilitative strategies might be put in place in order to optimize outcomes. Likewise, an individual primed to develop chronic pain by virtue of a previous TBI might experience greater pain due to a progressive disease such as osteoarthritis or diabetic neuropathy. These questions might be approached first by leveraging existing clinical and pharmacy outcomes data potentially available through organizations commonly treating TBI patients, including the DoD, VA, or perhaps trauma centers. These analyses will need to be carefully conducted as cofactors associated with both TBI and chronic pain such as PTSD are likely to be common [146] . Prospective trials examining pain, functional outcomes, and the efficacy of rationally selected interventions might then be designed.
Our understanding of the causes and consequences of pain after TBI is limited at this time despite TBI being a very common form of injury. Very substantial basic and clinical research challenges will need to be addressed in order to develop therapies in this context. On the other hand, interest in this area is growing, and we are likely to learn a good deal about the functioning of the nervous system and its response to injury in developing treatments for TBI-related pain. 
